Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Erasmus School of Health Policy and Management and Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam.
Rheumatology (Oxford). 2023 Feb 1;62(2):596-605. doi: 10.1093/rheumatology/keac397.
To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries.
A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit-risk trade-offs and predicted treatment uptake was subsequently calculated.
Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes.
Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics.
在三个国家量化对类风湿关节炎(RA)预防治疗的偏好。
通过调查小组在英国、德国和罗马尼亚招募成年人,进行了一项基于网络的调查,其中包括一项离散选择实验。参与者被要求假设他们正在经历关节痛,并且在接下来的 2 年内有 60%的机会患上 RA,并完成了 15 项无治疗和两种假设预防治疗之间的选择。治疗方法由六个属性(有效性、风险和频率/给药途径)定义,具有不同的水平。参与者还完成了一个具有固定特征的选择任务,反映了对候选预防治疗的主观估计。随后进行了潜在类别模型(LCM)分析,并计算了属性的相对重要性、获益-风险权衡以及预测的治疗使用率。
共纳入 2959 名参与者完成的调查。大多数参与者更喜欢治疗而不是不治疗,并且更看重降低风险的治疗效果,而不是其他属性。五类别 LCM 最适合数据。国家、RA 风险感知、健康素养和计算能力预测了类别成员概率。总体而言,接受 RA 风险降低 40%(60%降至 20%)的最大可接受风险分别为轻度副作用、严重感染和严重副作用的 21.7%、19.1%和 2.2%。反映候选预防治疗的固定治疗方案的预测采用率在不同类别之间存在差异。
RA 的有效预防药物治疗被大多数参与者所接受。治疗属性的相对重要性和候选预防治疗的固定治疗方案的可能采用率由参与者特征预测。